Postmarketing safety profile of brexanolone: many safety signals

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2023年 / 1980卷 / 1期
关键词：
D O I：
10.1007/s40278-023-48203-7
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：11 / 11
相关论文
共 50 条
  • [1] Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data
    Svetlana Garafola
    Elizabeth Shiferaw
    Vikram Dev
    Drugs - Real World Outcomes, 2023, 10 : 351 - 356
  • [2] Safety of Brexanolone in Adults with Postpartum Depression: Postmarketing Surveillance Data
    Garafola, Svetlana
    Shiferaw, Elizabeth
    Dev, Vikram
    DRUGS-REAL WORLD OUTCOMES, 2023, 10 (03) : 351 - 356
  • [3] Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)
    Zhang, Meilian
    Xie, Wenhuo
    Li, Jianbin
    Zheng, Jiaping
    Zhou, Yu
    ARCHIVES OF WOMENS MENTAL HEALTH, 2023, 27 (1) : 35 - 44
  • [4] Postmarketing safety profile of brexanolone: a pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS)
    Meilian Zhang
    Wenhuo Xie
    Jianbin Li
    Jiaping Zheng
    Yu Zhou
    Archives of Women's Mental Health, 2024, 27 : 35 - 44
  • [5] The postmarketing safety profile of varicella vaccine
    Sharrar, RG
    LaRussa, P
    Galea, SA
    Steinberg, SP
    Sweet, AR
    Keatley, RM
    Wells, ME
    Stephenson, WP
    Gershon, AA
    VACCINE, 2000, 19 (7-8) : 916 - 923
  • [6] Unraveling the Safety Profile of Biologicals Using Postmarketing Safety Data
    Giezen, T. J.
    Mantel-Teeuwisse, A. K.
    Straus, S. M. J. M.
    Meyboom, R. H. B.
    Leufkens, H. G. M.
    Egberts, A. C. G.
    DRUG SAFETY, 2009, 32 (10) : 966 - 967
  • [7] Postmarketing support for safety profile of DTaP vaccine
    Reactions Weekly, 2010, 1294 (1) : 3 - 3
  • [8] Postmarketing safety profile of sipuleucel-T
    Reactions Weekly, 2019, 1767 (1) : 10 - 10
  • [9] Postmarketing trials required to answer many drug safety questions
    Reactions Weekly, 2003, 975 (1) : 4 - 4
  • [10] Postmarketing safety profile of Agrylin for treatment of patients with thrombocythemia.
    Petrone, ME
    Beisser, G
    Tierney, D
    BLOOD, 1999, 94 (10) : 291B - 291B
12345